Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) is a clinical-stage company focused on oncology and obesity and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. Corbus’ pipeline includes CRB-701, a next-generation antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFβ expressed on cancer cells, and CRB-913, a highly peripherally restricted CB1 receptor inverse agonist for the treatment of obesity.
Looking for a particular Corbus Pharmaceuticals employee's phone or email?
Corbus Pharmaceuticals Questions
The Corbus Pharmaceuticals annual revenue was $15 million in 2026.
Yuval Cohen is the CEO of Corbus Pharmaceuticals.
44 people are employed at Corbus Pharmaceuticals.
Corbus Pharmaceuticals is based in Norwood, Massachusetts.
The NAICS codes for Corbus Pharmaceuticals are [325, 3254, 32541, 32].
The SIC codes for Corbus Pharmaceuticals are [28, 283].
Top Corbus Pharmaceuticals Employees
-
Yuval Cohen
Chief Executive Officer at Corbus Pharmaceuticals
New York, NY, US45+ -
Sean Moran
Chief Financial Officer at Corbus Pharmaceuticals
Norfolk, MA, US35+ -
G. Goeken
General Counsel at Corbus Pharmaceuticals
Stonington, CT, US35 -
Marshall Morningstar
Head of Chemistry at Corbus Pharmaceuticals
Waltham, MA, US25+ -
35+
-
Rodney Carter
Senior Director, Clinical Operations at Corbus Pharmaceuticals
Chapel Hill, NC, US45 -
15+
Related Companies
